This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sitsen, J. M. A. Articles by Timmer, C. J. Search for Related Content PubMed PubMed Citation Articles by Sitsen, J. M. A. Articles by Timmer, C. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LITHIUM COMPOUNDS LITHIUM, ELEMENTAL Social Bookmarking                         What's this?

Pharmacokinetics of mirtazapine and lithium in healthy male subjects

Clinical Development Department, Department of Drug Metabolism and Kinetics, NV Organon, PO Box 20, 5340 BH Oss, The Netherlands; j.sitsen{at}organon.oss.akzonobel.nl

G. Voortman

C. J. Timmer

Department of Drug Metabolism and Kinetics, NV Organon, The Netherlands

A substantial proportion of patients diagnosed with depression and treated with antidepressants show no or insufficient response. In such patients, lithium is often added to the antidepressant for augmentation. The present study investigated the possible drug–drug interaction between mirtazapine and lithium in 12 healthy male subjects in a randomized, double-blind, placebo-controlled two-period cross-over design. Subjects meeting the inclusion and exclusion criteria were randomly assigned to one of two groups. After an overnight fast, they received either a single oral dose of 600 mg lithium carbonate (16 meq Li⁺) for 10 days at 08.00 h and a single oral dose of 30 mg mirtazapine at 21.00 h on day 9 or the same number (n= 4) of placebo capsules and and a single oral dose of 30 mg mirtazapine at 21.00 h on day 9. At pre-defined times, blood samples were drawn for the measurement of mirtazapine plasma concentrations and lithium serum concentrations. In addition, psychometric tests were performed and the safety and tolerability of the drugs were assessed. The results indicate that mirtazapine does not alter the pharmacokinetics of lithium and vice versa. In addition, the combination of mirtazapine and lithium appeared to be safe and well-tolerated. Extensive psychometric testing after the administration of mirtazapine did not reveal any differences on any tests in subjects on lithium and placebo, respectively.

Key Words: antidepressant • drug—drug interaction • lithium • mirtazapine

Journal of Psychopharmacology, Vol. 14, No. 2, 172-176 (2000)
DOI: 10.1177/026988110001400207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?